Results 291 to 300 of about 755,181 (358)

A Physiological Microfluidic Blood–Brain‐Barrier Model for In Vitro Study of Nanoparticle Trafficking and Accumulation

Advanced Healthcare Materials, EarlyView.
A human microfluidic blood‐brain barrier (mBBB) model enables spatially resolved comparison of nanoparticle trafficking. Extracellular vesicles (EVs), liposomes, and nanoplastics exhibit distinct transport and disruption behaviors, revealing that membrane composition and uptake pathways govern BBB interaction.
Bryan B. Nguyen, Neona M. Lowe, Sophia Kellogg, Kuan‐Wei Huang, Hannah O'Toole, Elizabeth J. Hale, Venktesh S. Shirure, Bhupinder S. Shergill, Steven C. George, Randy P. Carney   +9 more
wiley   +1 more source

TAMs-mediated resistance to oncolytic virus M1 in solid tumors. [PDF]

J Immunother Cancer
Liang X, Li J, Chen J, Chen C, Li H, Yan C, Guo C, Han Y, Liu W, Sai K, Lin Y, Yan G, Zhu W, Liu Y.   +13 more
europepmc   +1 more source

Opinion: Gavage Administration of MXene as a Route‐Specific Alternative to Intravenous Injection into the Bloodstream of Laboratory Animals for Reducing Systemic Nanotoxicity Risks in Immunosuppression and Post‐Transplantation Models with Bile Acid Modification

Advanced Healthcare Materials, EarlyView.
Recent studies reported immunosuppressive properties of specific MXene nanomaterials. Their intravenous injection into the bloodstream of laboratory animals has been a common delivery method to suppress systemic inflammation and prevent transplant rejection.
Alireza Rafieerad, M. Akif Rahman, Ahmad Amiri   +2 more
wiley   +1 more source

Real-World Prevalence and Structural Validation of the Canonical 9p21 MTAP-CDKN2A/B Deletion in Non-NSCLC Solid Tumors. [PDF]

Cancers (Basel)
Han M, Lee E, Shin JE, Kwon M, Hong JY, Kim ST, Ahn S, Kim KM, Lee J, Lim SH.   +9 more
europepmc   +1 more source

Correction to: CAR NK cell therapy for solid tumors: potential and challenges. [PDF]

Antib Ther
europepmc   +1 more source

NN-01-195, a novel conjugate of HSP90 and AURKA inhibitors, effectively targets solid tumors. [PDF]

Mol Cancer Ther
Nguyen TT, Nandwana NK, Srikanth YVV, Bagnyukova T, Chkalo O, Cai KQ, Lamperelli J, Pirestani S, Mehra MK, Burtness BA, Borghaei H, Akunuri R, Cassel J, Lu L, Salvino JM, Golemis EA.   +15 more
europepmc   +1 more source

Translational Research on Solid Tumors: Bridging Molecular Insights and Clinical Impact. [PDF]

Cells
Urbini M, Ulivi P, Marisi G.
europepmc   +1 more source

Assessing the Impact of Comprehensive Genomic Profiling on Therapeutic Selection for Advanced Solid Tumors in Portugal. [PDF]

Curr Oncol
Tavares N, Simões P, Lopes-Brás R, Pacheco TR, Damaso S, Mansinho A, Ribeiro LA, Nogueira-Costa G, Abreu C, Barroso T, Bonito N, Figueiró R, Darmits B, Melo SL, Rodrigues T, Guedes H, Pratas E, Costa DA, Filipe FF, Macedo D, Cavaco A, Pavanello M, Costa L.   +22 more
europepmc   +1 more source

Denosumab Plus Immune Checkpoint Inhibitors in Bone Metastases From Solid Tumors. [PDF]

Cancer Control
Wang N, Song F, Li X, Chen H.
europepmc   +1 more source

Correction to: HER2 alterations across solid tumors: implications for comprehensive testing. [PDF]

Oncologist
europepmc   +1 more source